Disclosures under Regulation 62 of the SEBI LODR
Details of requirements mentioned in sub-regulation 1 of Regulation 62 of Listing Regulation
Notice of the Board meeting where financial results shall be discussed
- Notice for the 105th Statutory Board Meeting
- Notice for the 104th Statutory Board Meeting_Approval of FS_January 31, 2023
- Notice for the 103rd Statutory Board Meeting_Approval of FS_October 19, 2022
- Notice for the 102nd Statutory Board Meeting_Approval of FS_August 1, 2022
- Notice for the 101st Statutory Board Meeting_Approval of FS_May 10, 2022
- Notice for the 100th Statutory Board Meeting_Approval of FS_January 28, 2022
- Notice for the 99th Statutory Board Meeting_Approval of FS_November 9, 2021
- Notice for the 97th Statutory Board Meeting_Approval of FS_August 10, 2021
Disclosures/ Submissions/ Reports filed by the Company to the Stock exchange
- SubmissionOfAnnualReportFY23_Reg 53(2)_SEBILODR_MaxLife
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife
- IntimationToNSEReg51SEBI(LODR)MaxLifeMay122023
- NewspaperPublicationOfFinancialResults_Q4FY23_MaxLife
- DetailsOfIncrementalBorrowings_FY2023_ChapterXIIofSEBINCSoperationalcircular_MLIC
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateUnderRegulation61OfSEBILODRRegulations
- DisclosureUnderPara2OfChapterXIVOfNCSPperationalFrameworkMLIC
- Initial Disclosure to NSE_LC Under Chapter XII_SEBI Operational Circular_Max Life
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife_YE March 31 2023
- Compliance Certificate_Reg 3(5) & 3(6)of_SEBI(PIT) Regulations_March 31 2023
- DisclosureUnderReg7(1)oftheSEBILODRMaxLifeQEMarch312023
- DisclosureUnderReg6oftheSEBILODRMaxLifeQEMarch312023
- Intmation to NSE_Para 9.1 of Chapter XI of Ncs Operational Circular_March31, 2023
- StatementOfInvestorGrievances_Max Life_March 312023
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312023
- NewspaperpublicationOfQ3FY23ResultsMaxLife
- AuditedFinancialResultsAndSecurityCover_Dec312022_MaxLife_NSEDisclosure
- IntimationToNSE_Reg50_SEBILODR_MaxLife_January232023
- Compliance Certificate_Regulation 3(5) 3(6)_SEBI (PIT) Regulations_December 31 2022
- SubmissionOfRestatedAOAToNSE_January92023
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_January2023
- DisclosureUnderReg7oftheSEBILODRMaxLifeQEDecember312022
- DisclosureUnderReg6oftheSEBILODRMaxLifeDecember312022
- StatementOfInvestorGrievances_MaxLife_December312022
- IntimationtoNSE_TransferStakeOfMaxLifeByMSItoMFSL_Nov282022
- DisclosureUnder54(3)_Max Life
- NewspapaerPublicationOfQ2FY23Results_MaxLife
- AuditedFinancialResults_September302022_MaxLife_SEBILODR
- IntimationtoNSE_Reg50_SEBILODR_MaxLife_September2022
- Compliance Certificate_Regulation 3(5), 3(6)_SEBI (PIT) Regulations 2015_18.11.2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QESeptember302022
- StatementOfInvestorGrievances_MaxLife_September302022
- StatementUnderSEBINCSOperationCircularMaxLifeSeptember302022_Revised
- CertificateUnder57(5)_SEBILODR2015_MaxLife_Revised
- IntimationtoNSE_PressReleaseRegardingReceiptOfCOBbyMLPFM_MaxLife
- NewspaperPublicationOfQ1FY23Results_MaxLife
- CertificateOfInterestPaymentUnderReg57(1)_SEBILODR_MaxLife
- QuarterlyAuditedFinancialResults_QE30June2022_MaxLife
- SubmissionToNSE_Para2_ChapterXIVofNCSoperationalframework_MaxLife
- IntimationToNSE_Reg50_SEBILODR_MaxLife_June2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QE_june30_2022
- StatementOfInvestorGrievances_MaxLife_June302022
- IntimationtoNSEunderRegulation60(2)ofSEBILODR_MaxLife
- IntimationtoNSEunderRegulation57(4)OfSEBILODR_MaxLife
- NewspaperPublicationOfQ4AndFY22Results_MaxLife
- AssetCoverUnder54_MaxLife
- AuditedFinancialResults_March312022_MaxLife_SEBILODR
- AnnualReport_Reg53(2)_SEBILODR_MaxLife_10May2022
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife_May2022
- Initial Disclosure to NSE_LC_SEBI circular dated Nov 26, 2018
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife
- Disclosure Under Reg6and7 of the SEBILODR_MaxLife
- StatementOfInvestorGrievances_Max Life_March312022
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312022
- IntimationtoNSEForResignationofDyChiefFinancialOfficerMaxLife
- Intimation to NSE_Para 9.1 of Chapter XI of NCS operational framework_Ma
- IntimationForIncorporationOfWhollyOwnedSubsdiary
- Intimation To NSE_Reg50 SEBI LODR MaxLife January 28-01-2022
- Quarterly Financial Results December-31-2021 MaxLife
- Newspaper Publication Of Q3 FY22 Results MaxLife
- Intimation to NSE Regarding Reg6and7 of SEBI LODR MaxLife December-2021
- Statement of Investor Grievances MaxLife December 31 2021
- Certificate on Asset Coverage Ratio_September 30, 2021
- Intimation to NSE_Reg 6 and 7_SEBI LODR_MaxLife
- Intimation to NSE_Reg50_SEBI LODR_MaxLife_Nov 2, 2021
- Newspaper publication of Q2FY22 Results_MaxLife
- Statement for Utilisation of Proceeds_MaxLife_Sept 30, 2021
- Statement of Investor grievances_MaxLife_Sept 30, 2021
- Statement under SEBI circular dated August 10, 2021
Annual Report
| Year | FY-2022 | ||
| Download |
Credit Rating
Subordinated Debt Rating
Credit rating of subordinated debt reflects the degree of safety regarding timely servicing of financial obligations.
Rating Agency |
Rating |
Rating Date |
CRISIL |
CRISIL AA+ / Stable |
JUL-22 |
ICRA |
ICRA AA+ / Stable |
JUL-22 |
CRISIL |
CRISIL AA+ / Stable |
JUL-21 |
ICRA |
ICRA AA+ / Stable |
JUL-21 |
Email & Contact Information of the Designated Officials who are responsible for Assisting and Handling Investor Grievances
For investor grievances, please contact:
Anurag Chauhan
Company Secretary and Compliance Officer
Email: investorgrievance@maxlifeinsurance.com
Telephone: +91 124 412 1500
Email and Contact Information of the Debenture Trustee
IDBI Trusteeship Services Limited
Address: Asian Building, Ground Floor,
17 R. Kamani Marg, Ballard Estate
Mumbai- 400 001
Phone: 022 40807000
Email: itsl@idbitrustee.com
Website: www.idbitrustee.com